Abay Sisay1,2, Sonja Hartnack3, Abebaw Tiruneh1,4, Yasin Desalegn4, Abraham Tesfaye1,5, Adey Feleke Desta2. 1. Department of Medical Laboratory Sciences, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia. 2. Department of Microbial, Cellular and Molecular Biology, College of Natural and Computational Sciences, Addis Ababa University, Addis Ababa, Ethiopia. 3. Section of Epidemiology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland. 4. Addis Ababa Public Health Research and Emergency Management Laboratory, Addis Ababa Health Bureau, Addis Ababa, Ethiopia. 5. Diagnostic Unit, Center for Innovative Drug Development and Therapeutic Trials for Africa, CDT-Africa, Addis Ababa, Ethiopia.
Abstract
BACKGROUND: Rapid diagnostics are vital for curving the transmission and control of the COVID-19 pandemic. Although many commercially available antigen-based rapid diagnostic tests (Ag-RDTs) for the detection of SARS-CoV-2 are recommended by the WHO, their diagnostic performance has not yet been assessed in Ethiopia. So far, the vast majority of studies assessing diagnostic accuracies of rapid antigen tests considered RT-PCR as a reference standard, which inevitably leads to bias when RT-PCR is not 100% sensitive and specific. Thus, this study aimed to evaluate the diagnostic performance of Panbio™ jointly with the RT-PCR for the detection of SARS-CoV-2. METHODS: A prospective cross-sectional study was done from July to September 2021 in Addis Ababa, Ethiopia, during the third wave of the pandemic involving two health centers and two hospitals. Diagnostic sensitivity and specificity of Panbio™ and RT-PCR were obtained using Bayesian Latent-Class Models (BLCM). RESULTS: 438 COVID-19 presumptive clients were enrolled, 239 (54.6%) were females, of whom 196 (44.7%) had a positive RT-PCR and 158 (36.1%) were Panbio™ positive. The Panbio™ and RT-PCR had a sensitivity (95% CrI) of 99.6 (98.4-100) %, 89.3 (83.2-97.6) % and specificity (95% CrI) of 93.4 (82.3-100) %, and 99.1 (97.5-100) %, respectively. Most of the study participants, 318 (72.6%) exhibited COVID-19 symptoms; the most reported was cough 191 (43.6%). CONCLUSION: As expected the RT-PCR performed very well with a near-perfect specificity and a high, but not perfect sensitivity. The diagnostic performance of Panbio™ is coherent with the WHO established criteria of having a sensitivity ≥80% for Ag-RDTs. Both tests displayed high diagnostic accuracies in patients with and without symptoms. Hence, we recommend the use of the Panbio™ for both symptomatic and asymptomatic individuals in clinical settings for screening purposes.
BACKGROUND: Rapid diagnostics are vital for curving the transmission and control of the COVID-19 pandemic. Although many commercially available antigen-based rapid diagnostic tests (Ag-RDTs) for the detection of SARS-CoV-2 are recommended by the WHO, their diagnostic performance has not yet been assessed in Ethiopia. So far, the vast majority of studies assessing diagnostic accuracies of rapid antigen tests considered RT-PCR as a reference standard, which inevitably leads to bias when RT-PCR is not 100% sensitive and specific. Thus, this study aimed to evaluate the diagnostic performance of Panbio™ jointly with the RT-PCR for the detection of SARS-CoV-2. METHODS: A prospective cross-sectional study was done from July to September 2021 in Addis Ababa, Ethiopia, during the third wave of the pandemic involving two health centers and two hospitals. Diagnostic sensitivity and specificity of Panbio™ and RT-PCR were obtained using Bayesian Latent-Class Models (BLCM). RESULTS: 438 COVID-19 presumptive clients were enrolled, 239 (54.6%) were females, of whom 196 (44.7%) had a positive RT-PCR and 158 (36.1%) were Panbio™ positive. The Panbio™ and RT-PCR had a sensitivity (95% CrI) of 99.6 (98.4-100) %, 89.3 (83.2-97.6) % and specificity (95% CrI) of 93.4 (82.3-100) %, and 99.1 (97.5-100) %, respectively. Most of the study participants, 318 (72.6%) exhibited COVID-19 symptoms; the most reported was cough 191 (43.6%). CONCLUSION: As expected the RT-PCR performed very well with a near-perfect specificity and a high, but not perfect sensitivity. The diagnostic performance of Panbio™ is coherent with the WHO established criteria of having a sensitivity ≥80% for Ag-RDTs. Both tests displayed high diagnostic accuracies in patients with and without symptoms. Hence, we recommend the use of the Panbio™ for both symptomatic and asymptomatic individuals in clinical settings for screening purposes.
Authors: Polychronis Kostoulas; Søren S Nielsen; Adam J Branscum; Wesley O Johnson; Nandini Dendukuri; Navneet K Dhand; Nils Toft; Ian A Gardner Journal: Prev Vet Med Date: 2017-01-12 Impact factor: 2.670
Authors: Isabell Wagenhäuser; Kerstin Knies; Vera Rauschenberger; Michael Eisenmann; Miriam McDonogh; Nils Petri; Oliver Andres; Sven Flemming; Micha Gawlik; Michael Papsdorf; Regina Taurines; Hartmut Böhm; Johannes Forster; Dirk Weismann; Benedikt Weißbrich; Lars Dölken; Johannes Liese; Oliver Kurzai; Ulrich Vogel; Manuel Krone Journal: EBioMedicine Date: 2021-06-26 Impact factor: 8.143
Authors: Marie Thérèse Ngo Nsoga; Ilona Kronig; Francisco Javier Perez Rodriguez; Pascale Sattonnet-Roche; Diogo Da Silva; Javan Helbling; Jilian A Sacks; Margaretha de Vos; Erik Boehm; Angèle Gayet-Ageron; Alice Berger; Frédérique Jacquerioz-Bausch; François Chappuis; Laurent Kaiser; Manuel Schibler; Adriana Renzoni; Isabella Eckerle Journal: PLoS One Date: 2021-06-24 Impact factor: 3.240